Danaher Corporation is a leading global life sciences and diagnostics innovator, and the question for the next twelve months is whether the company can convert the $6.3 billion Q2 2026 revenue up 5.5% year over year, the 3.0% non-GAAP core revenue year over year growth, the 4.5% non-GAAP core revenue excluding respiratory testing revenue year over year growth, the $870 million Q2 2026 net earnings up 60% year over year, the $1.23 Q2 2026 diluted EPS up 60% year over year, the $1.94 Q2 2026 non-GAAP adjusted diluted net earnings per common share up 8.0% year over year, the $1.5 billion Q2 2026 operating cash flow, the $1.3 billion Q2 2026 non-GAAP free cash flow, the strong Q2 earnings performance, the earlier-than-anticipated completion of Masimo acquisition, the increased full year 2026 adjusted diluted net earnings per common share guidance to $8.45 to $8.60 from previous guidance of $8.35 to $8.55, the Life Sciences businesses delivered their strongest quarter in several years, the bioprocessing orders grew mid-teens in the quarter, the customer project timing impacted bioprocessing revenue, the underlying order trends remained strong, the continued end-market recovery, the traction from recent growth initiatives, the expectation to exit 2026 at a mid-single-digit core revenue growth rate, the longer term Danaher Business System positioning, the leading portfolio, the capital deployment optionality, the talented team, the powered by the Danaher Business System, the accelerate the impact of science and technology, the help customers move from discovery to delivery faster, the create sustainable long-term shareholder value, the Q3 2026 non-GAAP core revenue guidance of 2.0% to 3.0% year over year, the FY 2026 non-GAAP core revenue guidance of 3.0% to 4.0% year over year, the increased full year 2026 adjusted diluted net earnings per common share guidance to $8.45 to $8.60, the high-single-digits adjusted EPS growth, the disciplined execution, the strong underlying order trends, the mid-teens bioprocessing orders growth, the innovation at the speed of life positioning, and the leading global life sciences and diagnostics innovator positioning into the kind of Masimo-Integration and Bioprocessing-Recovery operating leverage the company has been telegraphing. The Q2 2026 print was the cleanest test of that thesis, and the cleanest signal is that President and CEO Rainer M. Blair said "we delivered a better than expected second quarter, with core growth improving versus the first quarter and disciplined execution driving high-single-digits adjusted EPS growth. Our Life Sciences businesses delivered their strongest quarter in several years and while customer project timing impacted bioprocessing revenue, underlying order trends remained strong and bioprocessing orders grew mid-teens in the quarter." The strategic tension is the customer project timing impacted bioprocessing revenue against the mid-teens bioprocessing orders growth, and the forward question is whether the Masimo integration and the bioprocessing recovery can compound the Life Sciences momentum into the raised FY2026 guidance the company has been telegraphing.
The $6.3 billion Q2 2026 revenue and the 5.5% year-over-year growth are the cleanest read on the operating momentum, and the earlier-than-anticipated completion of Masimo acquisition is the proof. The Q2 2026 revenue of $6.3 billion grew 5.5% above the prior-year quarter. The Q2 2026 non-GAAP core revenue grew 3.0% above the prior-year quarter. The Q2 2026 non-GAAP core revenue excluding respiratory testing revenue grew 4.5% above the prior-year quarter.
The Q2 2026 net earnings of $870 million grew 60% above the prior-year quarter. The Q2 2026 diluted EPS of $1.23 grew 60% above the prior-year quarter. The Q2 2026 non-GAAP adjusted diluted net earnings per common share of $1.94 grew 8.0% above the prior-year quarter. The Q2 2026 operating cash flow of $1.5 billion was the cleanest single read on the Q2 2026 operating cash flow the company is producing. The Q2 2026 non-GAAP free cash flow of $1.3 billion was the cleanest single read on the Q2 2026 non-GAAP free cash flow the company is producing.
The earlier-than-anticipated completion of Masimo acquisition, the increased full year 2026 adjusted diluted net earnings per common share guidance to $8.45 to $8.60 from previous guidance of $8.35 to $8.55, the Life Sciences businesses delivered their strongest quarter in several years, the bioprocessing orders grew mid-teens in the quarter, the customer project timing impacted bioprocessing revenue, the underlying order trends remained strong, the continued end-market recovery, the traction from recent growth initiatives, the expectation to exit 2026 at a mid-single-digit core revenue growth rate, the longer term Danaher Business System positioning, the leading portfolio, the capital deployment optionality, the talented team, the powered by the Danaher Business System, the accelerate the impact of science and technology, the help customers move from discovery to delivery faster, the create sustainable long-term shareholder value, the Q3 2026 non-GAAP core revenue guidance of 2.0% to 3.0% year over year, the FY 2026 non-GAAP core revenue guidance of 3.0% to 4.0% year over year, the high-single-digits adjusted EPS growth, the disciplined execution, the strong underlying order trends, the mid-teens bioprocessing orders growth, the innovation at the speed of life positioning, and the leading global life sciences and diagnostics innovator positioning anchor the print. The forward question is whether the Masimo integration and the bioprocessing recovery can compound the Life Sciences momentum.